FIELD: medicine. SUBSTANCE: proposed preparation contains human interferone and human immunoglobulins, their ratio being 1:600-300000. Human immunoglobulins are used as synergist. Recombinant human α, β or g-interferone is preferably used. Human immunoglobulins of 1GA, 1GM and 1GG types are used. Said preparation may contain pharmaceutical acceptable desired additives. EFFECT: improved quality. 4 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BIOLOGICALLY ACTIVE FOOD ADDITION | 1998 |
|
RU2125389C1 |
| PREPARATION POSSESSING ANTIVIRAL AND IMMUNOCORRECTING EFFECT | 2004 |
|
RU2262946C1 |
| METHOD OF PREPARING A RECOMBINANT ALFA-2-INTERFERON-BASE LYOPHILIZED PREPARATION AGAINST VIRAL DISEASES IN CARNIVORE ANIMALS | 1995 |
|
RU2121364C1 |
| AGENT FOR VIRUS DISEASES PREVENTION AND TREATMENT AND METHOD OF VIRUS DISEASES PREVENTION AND TREATMENT | 2007 |
|
RU2337703C1 |
| TEST SYSTEM FOR HUMAN INTERFERON ACTIVITY TESTING | 2013 |
|
RU2553431C2 |
| INTRANASAL ANTIVIRAL AGENT | 2023 |
|
RU2833350C1 |
| PREPARATION BASED UPON HUMAN RECOMBINANT ALPHA-2-INTERFERON FOR INJECTIONS IN DRY LYOPHILIZED FORM | 2002 |
|
RU2236866C2 |
| NON-PATHOGENIC STRAIN LEV82 OF HUMAN ENTEROVIRUS A, COXSACKIE SEROTYPE A7, FOR NON-SPECIFIC PREVENTION OF VIRAL INFECTIONS AND TREATMENT OF ONCOLOGICAL DISEASES | 2024 |
|
RU2824819C1 |
| PEPTIDE-IMMUNOREGULATOR (VERSIONS), MEDICINAL AGENT COMPRISING PEPTIDE-IMMUNOREGULATOR | 1998 |
|
RU2198178C2 |
| RECOMBINANT PLASMIDS pET32a-IFG144, PROVIDING INTERFERON GAMMA SYNTHESIS, BACTERIAL STRAIN ESCHERICHIA COLI JM109/pET32a-IFG144 - INTERFERON GAMMA PROTEIN PRODUCER, METHOD OF OBTAINING INTERFERON GAMMA AND MEDICINAL PRODUCT | 2022 |
|
RU2809358C1 |
